SAIC · Science Applications International Corp

Track SAIC — free

$127.56 -0.65 (-0.51%) At close · Sep 30

S&P 400 member Russell 1000 member Rebalance outlook locked

Market Cap

$5.56B

41.90M

Volume · Sep 30 348.95K Avg daily vol (3M) 454.44K

Up next

Next earnings call

Nov 30, 2026 Est · unconfirmed · in 9 wks

Latest filing: 10-Q

filed Aug 31, 2026

Q2 2027 earnings call transcript

call held Aug 31, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$7.40B

Trailing 12 months

Net income (TTM)

$380.00M

Trailing 12 months

Revenue growth YoY

+6.3%

Year over year

Operating margin

8.0%

Trailing 12 months

P / E (TTM)

15.0

Trailing earnings · reciprocal yield 6.7%

FCF yield

11.1%

TTM · current market cap

Return on invested capital

13.0%

Trailing 12 months

Net cash

−$2.36B

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

-8.5%

Year over year · fewer shares

Price change (1Y)

+31.2%

Trailing year

Short interest

5.4%

Latest settlement · 5.2 days to cover

View all 115 metrics

AI Brief

Q2 FY27 earnings call · Aug 31, 2026

Q2 FY27

TL;DR. SAIC delivered Q2 FY27 organic growth of 5.3% with 10.3% adjusted EBITDA margins and is raising full-year FY27 guidance for revenue (to $7.2B–$7.3B), adjusted EBITDA ($750M–$755M), and adjusted diluted EPS ($10.65–$10.75), while outlining Project Orbit targeting ~$150M in run-rate savings and a path to ~11% margins by FY30.

Bullish

+ Raised FY27 revenue, EBITDA, and EPS guidance on strong YTD performance.
+ Adjusted EBITDA margin of 10.3% with raised FY27 margin guidance to 10.3%–10.5%.
+ Net leverage fell to 3.0x, providing capital flexibility for M&A or further deleveraging.
+ Notable new awards including a $740M DHS recompete and a $400M intelligence agency recompete.

Bearish

− Quarterly book-to-bill of 0.6 and trailing 12-month of 0.8 reflects weak bookings.
− FY27 organic growth guide still implies contraction of 2% to flat due to RITS rolloff.
− Adjusted diluted EPS of $3.01 was down 17% year-over-year due to prior-year settlement.
− Second-half margins are expected to step down to high-9% range due to planned investments.
− Slower RFPs and awards are pushing opportunities to the right and pressuring near-term book-to-bill.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Very Bullish Fundamentals Strong Quant / Vol Moderate

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +19%

above

Price vs 50-day avg +1%

above

RSI (14) 46

neutral

MACD trend Negative

52-week position 88%

near high

Momentum

relative strength

Very Strong

1-month return +1%

trailing

6-month return +34%

trailing

YTD return +27%

this year

Relative strength +22%

vs S&P · 6-mo

Sentiment

smart money

Very Bullish

Trend (MA cross) No cross

50d $126 › 200d $107 — 50d above 200d

Institutional flow Accumulating

+3% holders QoQ · +63 funds added

Insider flow Accumulating

Net +$132.5K over 90 days · 0% sells

Short interest Falling

5.42% of float · ▼ -5.7% MoM · 5.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

436 holders — near 3-yr high, broad support

Squeeze score 62

elevated · 0–100

Fundamentals

Strong

Revenue growth −3%

Y/Y

EPS growth +7%

Y/Y

Free cash flow $577.0M

Valuation P/E 15.5

below peers

Buyback $4.3B

authorized

Balance sheet $248.0M

net debt

Quant / Vol

risk profile

Moderate

Volatility 39%

annualized · 1-yr

Max drawdown −28%

past year

ATR 2.9%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 3 of last 4

Latest guidance · from the 8-K filed Aug 31, 2026

Fiscal Year 2027

Adjusted EBITDA Non-GAAP Initiated $750M – $755M

Adjusted EBITDA Margin % Non-GAAP Initiated 10.3% – 10.5%

Free Cash Flow Non-GAAP Initiated at least $600M

Adjusted Diluted EPS Non-GAAP Initiated $10.65 – $10.75

FY27 Guidance

Net cash provided by operating activities Initiated at least $635M

Expenditures for property, plant, and equipment Initiated $35M

Guided vs delivered · last 4 settled

Revenue Fiscal Year 2025

guided $7.35B – $7.5B

guided $7.35B – $7.5B $7.48B In line

Revenue Fiscal Year 2024

guided $7.33B – $7.35B

guided $7.33B – $7.35B $7.44B Beat +1.5%

Revenue fiscal year 2022

guided $7.35B – $7.4B

guided $7.35B – $7.4B $7.39B In line

Revenue fiscal year 2021

guided $7.1B – $7.2B

guided $7.1B – $7.2B $7.06B Miss −1.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+19% Bullish

Price vs 50-day avg

+1% Bullish

RSI (14)

46 Neutral

MACD trend

Negative Bearish

52-week position

88% Bullish

Market signals — smart money & positioning

Bullish · 4 of 6

Trend (MA cross) No cross

50d $126 › 200d $107 — 50d above 200d

Institutional flow Accumulating

+3% holders QoQ · +63 funds added

Insider flow Accumulating

Net +$132.5K over 90 days · 0% sells

Short interest Falling

5.42% of float · ▼ -5.7% MoM · 5.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

436 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $82 Now $128 · 88% Range high $134

vs 200-day avg +19% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted Diluted EPS non-GAAP	$6.24	Six Months Ended July 31, 2026	—
Adjusted EBITDA non-GAAP	$193M	Q2 FY2027	+0.0%

GAAP → non-GAAP reconciliation GAAP EBITDA 193M +2M Acquisition, integration, restructuring and impairment costs -1M Recovery of acquisition, integration, restructuring and impairment costs +0M Costs related to the settlement of federal tax audits -1M Gain on divestitures, net of transaction costs = Adjusted EBITDA 193M
Adjusted EBITDA as a percentage of revenues non-GAAP	10.3%	Q2 FY2027	+0.0%

Adjusted operating income non-GAAP	$191M	Three Months Ended July 31, 2026 filing	+0.0%

GAAP → non-GAAP reconciliation GAAP Operating income $152M +$7M Depreciation of property, plant and equipment +$32M Amortization of intangible assets +$2M Acquisition, integration, restructuring and impairment costs -$1M Recovery of acquisition, integration, restructuring and impairment costs +$0M Costs related to the settlement of federal tax audits -$1M Gain on divestitures, net of transaction costs = Adjusted operating income $191M
EBITDA non-GAAP	$413M	Six Months Ended July 31, 2026	—
EBITDA as a percentage of revenues non-GAAP	10.3%	Three Months Ended July 31, 2026 filing	—
Estimated backlog	22.1B	Q2 FY2027	—
Free cash flow non-GAAP	$131M	Q2 FY2027	+0.0%

GAAP → non-GAAP reconciliation GAAP Net cash provided by operating activities 146M -15M Expenditures for property, plant, and equipment +0M Cash used from (provided by) MARPA Facility = Free cash flow 131M
Funded backlog	3.8B	Q2 FY2027	—
Negotiated unfunded backlog	$18.32B	July 31, 2026	—
Net bookings	1.2B	Q2 FY2027	+0.0%

Organic growth non-GAAP	5.3%	Q2 FY2027	—
Quarterly book-to-bill ratio	0.6	Q2 FY2027	—
Total adjusted operating income non-GAAP	$412M	Six Months Ended July 31, 2026	—
Total adjusted operating margin non-GAAP	10.9%	Six Months Ended July 31, 2026	—
Total backlog	$22.14B	July 31, 2026	—
Trailing twelve months book-to-bill ratio	0.8	Q2 FY2027	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Information Technology Services — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
SAIC Science Applications International Corp this stock	$5.56B	+26.7%	-2.9%	15.5	5.4%
IBM International Business Machines Corp	$212.46B	-25.8%	+7.6%	20.0	2.4%
ACN Accenture plc	$116.59B	-31.7%	+7.4%	14.0	3.7%
INFY Infosys Ltd	$42.53B	-39.6%	—	—	3.1%
CTSH Cognizant Technology Solutions Corp	$27.26B	-30.8%	+7.0%	12.5	7.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

436

% held: 86.5%
Net QoQ: +148.3K sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

395

View

Short & Settlement

Short Interest Falling

Shares short

2.3M

Days to cover: 5.2d
Change: -138.5K sh

View

Short Volume

Short vol %

55%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

1.3K

Value: $167.3K
As of: Sep 9, 2026

View

Off-Exchange

Off-exchange %

46.0%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$132.5K

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Congressional Trades Sell

Member

Lisa McClain

Amount: $1.0K–$15.0K
Traded: Oct 31, 2025

View

Financials

Revenue (FY)

$7.3B

Net income (FY): $358.0M
EPS diluted: $7.70

View

Buybacks

Authorized · 3 programs

$4.3B

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 31, 2026
This year: 18

View

Proposed Sales

Value

$368.5K

Shares: 3.2K
Filed: Jan 13, 2025

View

Earnings & Events

Earnings Calls

Last call

Aug 31, 2026

View

Performance

	5D	20D	120D	MTD	YTD
SAIC	-4.1%	+0.6%	+34.2%	-0.5%	+26.7%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	-3.4%	+0.5%	+22.1%	+0.1%	+14.9%

Capital returns

Buyback programs · 3 active · as of Jul 31, 2026

Authorized (total)

$4.26B

Spent (derived)

—

Remaining

—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1571123 CUSIP 808625107 13F (30d) 13 filings 13 filers Visit website Investor relations

SAIC · Science Applications International Corp

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns